Dr. Neil Bodie and colleagues at Paradigm Immunotherapeutics along with collaborators at Kyoto University and Michigan State University have reported on the design of an ultra-high affinity ACE2 variant that has been coupled to an Fc domain incorporating mAbsolve’s STR mutations for silencing and the YTE mutations for half-life extension. It is hoped that this … Read more
Genscript ProBio have licenced mAbsolves first in class solution for abolising antibody effector function to enable their worldwide client base to access the technology in the early research phases of their antibody development projects. The full press release can be accessed below.
On Thursday 22nd September, our CEO, Geoff Hale, will be presenting some of our recent work on the analysis of Fc sequences from antibodies and Fc fusion proteins and the range of variants used for Fc silencing. Abstract: Over the last 40 years, antibodies and antibody-related biologics have probably been the greatest growth area for … Read more
Today our CEO and CSO, Geoff Hale and Ian Wilkinson, have had a new article published in mAbs. The work described in the article started as an internal effort to better understand the number of silenced antibodies in clinical development and the mutations they used. However, the goal of this work broadened out very quickly … Read more
On Saturday 10th September our CSO, Ian Wilkinson, will be giving a webinar to the Chinese Antibody Society on Fc silencing. To sign up click here. Abstract: Antibodies are nature’s pro-drugs, wonderfully evolved to target pathogens and activate immune systems. For certain indications where ADCC or CDC are required this is ideal, however, for many … Read more
On 5 Jul 2022 the UK Intellectual Property Office granted Patent number GB2595299 to mAbsolve. Publication of the patent is expected on 3 Aug 2022. The patent claims cover a range of variants in the immunoglobulin Fc region which effectively eliminate binding to Fc gamma receptors and associated cellular activation, without adverse effects on manufacturability, … Read more
Scancell, a UK based company developing anti-glycan antibodies, have today announced an agreement with mAbsolve to license our STR technology for Fc silencing. Full details available in the press release below.
Fully silent antibodies as true negative controls for in vitro and cell-based effector function assays Antibody Analytics Ltd., a leading provider of antibody effector function characterisation and immunology research services, and mAbsolve, developers of a novel Fc silencing variant, today announced a licensing deal for mAbsolve’s Fc silencing technology. The agreement provides Antibody Analytics with … Read more
Our CSO, Ian Wilkinson, will be attending PEGS Boston in the week of 2-6th May. Our antibody silencing technology will be on display all week at poster 94.
Our CSO, Ian Wilkinson, will be presenting on the importance of attenuating effector functions in therapeutics antibodies as part of the Antibody Discovery & Development webinar series being run by The Antibody Society. The event will be held on 28th April and is free to attend. To attend please sign up here. In this webinar Ian … Read more